NCT00593047View on ClinicalTrials.gov

LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin

PHASE2CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions

Dyslipidemia

Interventions

DRUG

KB2115

tablet formulation given once daily for 12 weeks

Trial Locations (1)

Unknown

Carl-Peter Anderberg, Gothemburg

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Karo Bio AB

INDUSTRY